Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Claire Long

Bayer symbol

Bayer moves vilaprisan into phase III trials for uterine fibroids

ASTEROID study will investigate safety and efficacy of the novel drug

- PMLiVE

Public affairs and policy prize at Communiqué for Incisive Health

Agency also picks up accolades for its media, payer and writing work

- PMLiVE

Clark Health wins Small Consultancy of the Year

Communiqué judges praised the agency as ‘authentic’ and ‘trustworthy’

Rainer Boehm and Hervé Hoppenot join Cellectics board

French biopharma firm adds senior industry advisors

- PMLiVE

Untreatable gonorrhoea on the march worldwide, says WHO

Three people with the STI aren’t responding to last-line antibiotics

- PMLiVE

Lucid Group’s winning formula is recognised at Communiqué 2017

Lucid Group’s commitment to improving patient outcomes across the globe was recognised at the 2017 Communiqué Awards in London last night. The agency won the awards for Excellence in Communications...

Lucid Group Communications Limited

- PMLiVE

90TEN named Communiqué Consultancy of the Year 2017

Agency's haul at the awards also included Med Ed Consultancy of the Year

New agency launched

Pharma companies don’t need another vanilla agency

An agency called Owen

Immunotherapies in oncology: the future of cancer treatment lies in combinations and partnerships

Anne Legendre reviews the scientific rationale behind immunotherapy combinations and Frances Hendry examines how partnerships, co-marketing and positioning drugs will play key roles in shaping the competitive landscape in oncology.

Blue Latitude Health

- PMLiVE

Standing out in a crowd

Celltrion Healthcare’s Ho-Ung Kim on pricing, market access and regulatory challenges for successfully developing biosimilars

- PMLiVE

FDA halts third Merck myeloma trial after patient deaths

More patients died on Keytruda combination than those on other treatments

Bristol-Myers Squibb (BMS) building

Opdivo tops Yervoy in adjuvant melanoma trial

BMS’ nivolumab reduced the recurrence rate of melanoma compared to Yervoy

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links